• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Ligand binding assays at equilibrium: validation and interpretation.平衡态配体结合分析:验证与解读。
Br J Pharmacol. 2010 Nov;161(6):1219-37. doi: 10.1111/j.1476-5381.2009.00604.x.
2
Practical aspects of radioligand binding.放射性配体结合的实践方面。
Curr Protoc Pharmacol. 2006 Jul;Chapter 1:Unit1.3. doi: 10.1002/0471141755.ph0103s33.
3
Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.用“两步”竞争结合法估计未标记配体-受体复合物的离解速率。
Br J Pharmacol. 2010 Nov;161(6):1311-28. doi: 10.1111/j.1476-5381.2010.00931.x.
4
Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds.测量受体靶点覆盖率:一种用于评估未标记化合物结合和解离速率的放射性配体竞争结合方案。
Curr Protoc Pharmacol. 2010 Sep;Chapter 9:Unit 9.14. doi: 10.1002/0471141755.ph0914s50.
5
Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors.在改良的高亲和力放射性配体受体结合方案中重新研究受体和配体的浓度:[3H]螺哌隆与 D2 和 D3 多巴胺受体的结合。
J Neurosci Methods. 2010 Apr 30;188(1):32-8. doi: 10.1016/j.jneumeth.2010.01.031. Epub 2010 Feb 1.
6
Radioligand Binding Assays for Determining Dissociation Constants of Phytohormone Receptors.用于测定植物激素受体解离常数的放射性配体结合分析
Methods Mol Biol. 2016;1450:23-34. doi: 10.1007/978-1-4939-3759-2_3.
7
GPCR-radioligand binding assays.G蛋白偶联受体放射性配体结合测定
Methods Cell Biol. 2016;132:191-215. doi: 10.1016/bs.mcb.2015.11.004. Epub 2016 Feb 10.
8
Ligand dissociation constants from competition binding assays: errors associated with ligand depletion.竞争结合试验中的配体解离常数:与配体耗竭相关的误差
Mol Pharmacol. 1987 Jun;31(6):603-9.
9
Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. elusive equilibrium:使用钙测定法解释受体药理学的挑战。
Br J Pharmacol. 2010 Nov;161(6):1250-65. doi: 10.1111/j.1476-5381.2010.00863.x.
10
A competitive binding assay for 2,3,7,8-tetrachlorodibenzo-p-dioxin and related ligands of the Ah receptor.一种针对2,3,7,8-四氯二苯并对二恶英及芳烃受体相关配体的竞争性结合分析方法。
Mol Pharmacol. 1988 Nov;34(5):682-8.

引用本文的文献

1
Covalent Drug Binding in Live Cells Monitored by Mid-IR Quantum Cascade Laser Spectroscopy: Photoactive Yellow Protein as a Model System.通过中红外量子级联激光光谱监测活细胞中的共价药物结合:以光活性黄色蛋白为模型系统
bioRxiv. 2025 Aug 19:2025.08.15.670201. doi: 10.1101/2025.08.15.670201.
2
How THC works: Explaining ligand affinity for, and partial agonism of, cannabinoid receptor 1.四氢大麻酚的作用机制:解释其对大麻素受体1的配体亲和力和部分激动作用。
iScience. 2025 May 21;28(7):112706. doi: 10.1016/j.isci.2025.112706. eCollection 2025 Jul 18.
3
Design a multi-epitope vaccine candidate against Acinetobacter baumannii using advanced computational methods.使用先进的计算方法设计一种针对鲍曼不动杆菌的多表位疫苗候选物。
AMB Express. 2025 Jul 12;15(1):103. doi: 10.1186/s13568-025-01913-6.
4
Anti-IgD nanobodies as novel tools for studying human IgD biology.抗IgD纳米抗体作为研究人类IgD生物学的新型工具。
Sci Rep. 2025 Jul 8;15(1):24455. doi: 10.1038/s41598-025-09118-4.
5
Adiabatic-Bias Molecular Dynamics Simulations Reveal the Impact of Mutations on Muscarinic Antagonist Unbinding Kinetics.绝热偏置分子动力学模拟揭示突变对毒蕈碱拮抗剂解离动力学的影响。
J Chem Inf Model. 2025 Jul 14;65(13):7129-7142. doi: 10.1021/acs.jcim.5c00601. Epub 2025 Jun 16.
6
Interactions of Ligand, Aptamer, and Complementary Oligonucleotide: Studying Impacts of Na and Mg Cations on Sensitive FRET-Based Detection of Aflatoxin B1.配体、适配体和互补寡核苷酸的相互作用:研究钠和镁阳离子对基于荧光共振能量转移的黄曲霉毒素B1灵敏检测的影响
Molecules. 2025 May 11;30(10):2125. doi: 10.3390/molecules30102125.
7
Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer.在乳腺癌动物模型中对一种PARP抑制剂的简化放射性标记方法的评估。
EJNMMI Res. 2025 Apr 29;15(1):50. doi: 10.1186/s13550-025-01236-4.
8
Further In Vitro and Ex Vivo Pharmacological and Kinetic Characterizations of CCF219B: A Positive Allosteric Modulator of the α-Adrenergic Receptor.CCF219B的进一步体外和离体药理学及动力学特性:一种α-肾上腺素能受体的正变构调节剂
Pharmaceuticals (Basel). 2025 Mar 27;18(4):476. doi: 10.3390/ph18040476.
9
New acridone derivatives to target telomerase and oncogenes - an anticancer approach.靶向端粒酶和癌基因的新型吖啶酮衍生物——一种抗癌方法。
RSC Med Chem. 2025 Apr 17. doi: 10.1039/d4md00959b.
10
A Robust Expression and Purification Protocol for the Production of the La Domain of Human LARP6.一种用于生产人LARP6的La结构域的稳健表达和纯化方案。
ACS Omega. 2025 Mar 19;10(12):12699-12709. doi: 10.1021/acsomega.5c01045. eCollection 2025 Apr 1.

本文引用的文献

1
Membrane depolarization causes a direct activation of G protein-coupled receptors leading to local Ca2+ release in smooth muscle.膜去极化导致G蛋白偶联受体直接激活,进而引起平滑肌局部钙离子释放。
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11418-23. doi: 10.1073/pnas.0813307106. Epub 2009 Jun 19.
2
The role of binding kinetics in therapeutically useful drug action.结合动力学在具有治疗作用的药物效应中的作用。
Curr Opin Drug Discov Devel. 2009 Jan;12(1):31-9.
3
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.G蛋白偶联受体的变构调节剂:一种治疗中枢神经系统疾病的新方法。
Nat Rev Drug Discov. 2009 Jan;8(1):41-54. doi: 10.1038/nrd2760.
4
Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors.诱变图谱揭示了M1毒蕈碱型乙酰胆碱受体选择性激动剂的一种新型结合模式。
Mol Pharmacol. 2009 Feb;75(2):331-41. doi: 10.1124/mol.108.050963. Epub 2008 Nov 11.
5
Do enthalpy and entropy distinguish first in class from best in class?焓和熵在同类中是首先区分出来的,还是同类中最好的?
Drug Discov Today. 2008 Oct;13(19-20):869-74. doi: 10.1016/j.drudis.2008.07.005. Epub 2008 Aug 26.
6
Limitations and lessons in the use of X-ray structural information in drug design.药物设计中X射线结构信息使用的局限性与经验教训。
Drug Discov Today. 2008 Oct;13(19-20):831-41. doi: 10.1016/j.drudis.2008.06.006. Epub 2008 Aug 27.
7
Structure of a beta1-adrenergic G-protein-coupled receptor.β1-肾上腺素能G蛋白偶联受体的结构
Nature. 2008 Jul 24;454(7203):486-91. doi: 10.1038/nature07101. Epub 2008 Jun 25.
8
Scintillation proximity assays in high-throughput screening.高通量筛选中的闪烁邻近分析
Assay Drug Dev Technol. 2008 Jun;6(3):433-55. doi: 10.1089/adt.2008.135.
9
Guide to Receptors and Channels (GRAC), 3rd edition.《受体与通道指南》(GRAC),第三版。
Br J Pharmacol. 2008 Mar;153 Suppl 2(Suppl 2):S1-209. doi: 10.1038/sj.bjp.0707746.
10
The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.正构放射性配体耗竭对变构调节剂相互作用定量的影响。
J Pharmacol Exp Ther. 2008 Jun;325(3):927-34. doi: 10.1124/jpet.108.136978. Epub 2008 Mar 5.

平衡态配体结合分析:验证与解读。

Ligand binding assays at equilibrium: validation and interpretation.

机构信息

Division of Physical Biochemistry, MRC National Institute for Medical Research, Mill Hill, London, UK.

出版信息

Br J Pharmacol. 2010 Nov;161(6):1219-37. doi: 10.1111/j.1476-5381.2009.00604.x.

DOI:10.1111/j.1476-5381.2009.00604.x
PMID:20132208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3000649/
Abstract

The focus of this review paper is factors affecting data interpretation in ligand binding assays under equilibrium conditions. Protocols for determining K(d) (the equilibrium dissociation constant) and K(dA) (the equilibrium inhibitor constant) for receptor ligands are discussed. The basic theory describing the interaction of a radiotracer and an unlabelled competitor ligand with a receptor is developed. Inappropriate experimental design may result in ligand depletion and non-attainment of equilibrium, distorting the calculation of K(d) and K(dA) . Strategies, both theoretical and practical, will be given to avoid and correct such errors, thus leading to the determination of reliable values for these constants. In determining K(dA) from competition binding studies, two additional concepts are discussed. First, the necessity to measure an adequate specific binding signal from the bound radiotracer ligand limits the range of affinity constants that can be measured: a particular set of assay conditions may lead to an upper limit on the apparent affinity of unlabelled ligands. Second, an extension of the basic assay methodology can indicate whether the interaction between the tracer and a test ligand is mediated by a competitive or an allosteric mechanism. Finally, the review ends with a discussion of two factors that are often overlooked: buffer composition and the temperature at which the assay is conducted, and the impact these can have on affinity measurements and the understanding of drug interactions.

摘要

这篇综述论文的重点是讨论在平衡条件下影响配体结合分析中数据解释的因素。讨论了用于确定受体配体的 K(d)(平衡解离常数)和 K(dA)(平衡抑制剂常数)的方案。阐述了描述放射性示踪剂和未标记竞争配体与受体相互作用的基本理论。不适当的实验设计可能导致配体耗尽和未达到平衡,从而扭曲 K(d)和 K(dA)的计算。将给出理论和实际的策略来避免和纠正这些错误,从而确定这些常数的可靠值。在从竞争结合研究中确定 K(dA)时,讨论了另外两个概念。首先,必须从结合的放射性示踪配体中测量足够的特异性结合信号,这限制了可以测量的亲和力常数的范围:特定的一组测定条件可能导致未标记配体的表观亲和力的上限。其次,基本测定方法的扩展可以表明示踪剂和测试配体之间的相互作用是由竞争性还是变构机制介导的。最后,讨论了两个经常被忽视的因素:缓冲液组成和测定进行的温度,以及这些因素对亲和力测量和药物相互作用的理解的影响。